Medison, the creator and leader of the global partnership category, has built the first-of-its-kind unified commercialization platform, empowering biotech to plan, optimize, and launch their therapies on a global scale
Medison Pharma in Australia and New Zealand is a pioneer in the healthcare landscape as the first to focus solely on commercializing breakthrough therapies, helping to save and improve the lives of patients in the region suffering from rare and severe diseases by accelerating access to the best available novel treatments.
With established regional presence and deep expertise in local regulatory and market access, Medison Pharma offers an affiliate-like partnership, enabling biotech to expand their reach into the Australia-New Zealand market.
List of Medicines (Australia):
Below is a list of medicines that Medison currently markets in Australia, including Product Information (for healthcare professionals) and Consumer Medicine Information (for consumers). Australian regulations do not allow pharmaceutical companies to offer medical advice on the diagnosis of disease or choice of therapy to consumers. Please consult with your healthcare professional.
Please refer to the Therapeutic Goods Administration (TGA) Website for additional information on our products.
This website contains information intended for residents of Australia only.
KIMMTRAK® (tebentafusp)
LIBTAYO® (cemiplimab)
ONPATTRO® (patisiran)
AMVUTTRA® (vutrisiran)
OXLUMO® (lumasiran)
Contact Us:
For general enquiries, fill in the form or email us infoaustralia@medisonpharma.
Head Office
Medison Pharma Australia
Registered Business Address: 1 Bligh Street, Sydney NSW 2000
Business Address: Suite 7.01, 465 Victoria Avenue, Chatswood NSW 2067
Business phone number: +61 2 7233 0244
To report an adverse event email: safety.australia@medisonpharma.com
For medical information enquiries email: medinfo.australia@
Medical information phone number: 1800 566 020 (Australia)